Scott Herbert, MD
Hematology & Oncology · Albuquerque, NMNPI 1548340870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 711 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations.
Across 711 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$1K
- Gilead$960
- E.r. Squibb & Sons, L.L.C.$846
- Johnson & Johnson$835
- Incyte Corporation$713
- plus $8K from 54 others
Across 19 payments — averaging $13,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$136K
- Merck$118K
What the payments were for
- Food & beverage$13,43095%
- Education$6995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,129 in reported general payments places this provider in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 52 | $726,116 |
| ImbruvicaIbrutinib | 40 | $583,959 |
| Lenalidomide | 30 | $438,579 |
| RevlimidLenalidomide | 13 | $288,285 |
| OrserduElacestrant Hcl | 12 | $273,729 |
| BesremiRopeginterferon Alfa-2b-Njft | 15 | $252,229 |
| VerzenioAbemaciclib | 14 | $210,990 |
| Abiraterone Acetate | 59 | $165,025 |
| PromactaEltrombopag Olamine | 15 | $150,701 |
| Pazopanib Hcl | 14 | $115,838 |
| Bexarotene | 12 | $50,013 |
| XareltoRivaroxaban | 24 | $20,501 |
| Hydroxyurea | 38 | $1,347 |
| Letrozole | 51 | $1,184 |
| Dexamethasone | 53 | $1,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $104 | $726,11652 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $61 | $583,95940 claims |
| Bristol Myers SquibbRevlimid | $511 | $288,28513 claims |
| Stemline Therapeutics Inc.Orserdu | $80 | $273,72912 claims |
| Pharmaessentia USA CorporationBesremi | $80 | $252,22915 claims |
| Lilly USA, LLCVerzenio | $131 | $210,99014 claims |
| NovartisPromacta | $1,328 | $150,70115 claims |
| Johnson & JohnsonXarelto | $835 | $20,50124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
- Bernard TawfikAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.